| 2026-10-26 17:20 |
PREM14A |
|
merger agreement |
0.98
|
Skye Bioscience acquiring Redx Pharma via scheme of arrangement; definitive transaction agreement with stockholder vote required. |
SEC · detail |
| 2026-09-11 16:13 |
8-K |
["1.02", "5.02", "8.01"] |
merger agreement |
0.92
|
Skye Bioscience announced proposed acquisition of Redx Pharma Limited with proxy statement forthcoming. |
SEC · detail |
| 2026-08-24 16:02 |
8-K |
["1.01"] |
merger agreement |
0.85
|
Material definitive merger agreement with Redx Pharma Limited signed August 14, 2026; concurrent PIPE financing and investor commitment. |
SEC · detail |
| 2026-08-19 21:42 |
8-K |
["3.03"] |
merger agreement |
0.92
|
Skye Bioscience filing soliciting material for proposed acquisition of Redx Pharma Limited; proxy statement pending. |
SEC · detail |
| 2026-08-18 19:56 |
8-K |
["3.01"] |
merger agreement |
0.92
|
Skye Bioscience acquiring Redx Pharma Limited; proxy statement planned for stockholder vote. |
SEC · detail |
| 2026-08-14 09:36 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Skye Bioscience entered definitive merger agreement to acquire Redx Pharma via scheme of arrangement; stock deal with concurrent financing. |
SEC · detail |
| 2026-06-22 17:53 |
8-K |
["8.01"] |
other |
0.05
|
Nasdaq listing downgrade due to insufficient stockholders' equity and minimum bid price; no M&A signal. |
SEC · detail |
| 2026-05-29 16:54 |
8-K |
["5.03", "5.07", "9.01"] |
other |
0.25
|
Routine annual meeting with charter amendment increasing authorized shares; no M&A signals detected. |
SEC · detail |
| 2026-05-15 16:00 |
8-K |
["3.01"] |
other |
0.15
|
Nasdaq delisting notice due to insufficient stockholders' equity; financial distress, not M&A signal. |
SEC · detail |